CytoSorbents releases investor presentation on blood purification devices for ICU, cardiac surgery use

• CytoSorbents highlighted trailing 12-month sales of $37.3 million through June 30, 2026, with 72% gross margins.
• Management flagged Q2 2026 operating cash burn of about $200K, excluding restructuring costs, with cash flow breakeven targeted in H2 2026.
• CytoSorb remains CE-marked in Europe, with more than 300,000 treatments across 70-plus countries; not cleared in the U.S. or Canada.
• DrugSorb-ATR positioned as the key North America catalyst, with two FDA Breakthrough Device designations; device remains investigational.
• DoD-backed HEMODEFEND-BGA program cited with $16 million in funding, targeting a “universal plasma” approach; preclinical ahead of human trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.